Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Zepbound (tirzepatide) is a weekly injectable weight-loss medication. It can be purchased online or in person with a valid ...

Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Zepbound (tirzepatide) is a prescription drug that’s used for weight loss and obstructive sleep apnea in certain adults. Zepbound comes as a liquid solution inside prefilled injection pens.

Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...

Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.